While the world awaits widespread vaccination and herd immunity, hundreds of thousands of COVID-19 cases are confirmed and thousands of people die each day. With such staggering statistics, it’s important that we focus on both treatment and prevention. The team at VCU’s Medicines for All (M4ALL) Institute are working to ensure that effective therapies can be produced in a cost-effective, scalable way, so they are accessible to all who need them. They recently announced completion and publication of a new synthesis for molnupiravir. This straightforward, two-step route is now available for interested manufacturers to follow.
The Arcady Group has worked with the M4ALL team since the institute’s inception – helping to develop the organization’s strategy, secure funding from the Bill & Melinda Gates Foundation, and connect key stakeholders and ideas. Today we are proud to engage regularly in an advisory capacity, especially on matters related to M4ALL funder and market engagement.
We are encouraged and inspired by this work, which stands to improve access to life-saving medications, particularly in high-burden regions of the world.